Last updated: February 13, 2026
What Is the Market Position and Pricing Outlook for NDC 21922-0036?
The drug with NDC 21922-0036 corresponds to Sparsentan (brand name: Jes_sq), an anti-fibrotic agent developed by Retrophin (now part of Travere Therapeutics), primarily targeting rare kidney diseases such as focal segmental glomerulosclerosis (FSGS) and primary membranous nephropathy (pMN).
How Large Is the Market for Sparsentan?
Market Size Estimates
-
FSGS and pMN Incidence: FSGS affects approximately 7-16 cases per million population annually in the U.S. (source: Nephrology Dialysis Transplantation [1]). pMN has an estimated incidence of 1-2 per 100,000 (source: Kidney International [2]).
-
Prevalent Patient Population: Combining indications, approximately 20,000–30,000 patients might be eligible for Sparsentan worldwide, with approximately 10,000–15,000 in the U.S.
Market Penetration Potential
-
Orphan Drug Status: Both indications qualify as rare diseases, enabling exclusive rights and potential premium pricing.
-
Market Adoption Factors: Efficacy data from ongoing Phase 3 trials, safety profile, and competitor landscape influence market penetration. Adoption may initially be limited to specialized nephrology centers.
What Are Current Pricing Trends for Rare Disease Drugs?
-
Pricing Range: Rare disease drugs in the nephrology space typically retail at $50,000 to $150,000 per patient per year.
-
Sparsentan’s Expected Price: Based on comparable drugs, initial pricing could be around $100,000 to $125,000 annually. The price reflects its orphan status, the severity of the diseases, and limited patient populations.
-
Reimbursement Landscape: Insurance coverage, particularly Medicare and Medicaid, influences actual prices paid. Managed care organizations favor high-cost drugs if clinical benefits are substantial.
What Are the Price Projections?
Short-term (1–2 years post-approval)
-
Initial Price Point: Expect approximately $100,000–$125,000 annually, aiming to recoup R&D costs and leverage orphan drug exclusivity.
-
Market Penetration: Limited initial uptake, 10–20% of eligible patients, due to clinician familiarity and reimbursement processes.
Medium-term (3–5 years post-approval)
-
Price Stabilization or Slight Increase: Slight increases to $125,000–$150,000 per year, reflecting inflation and expanded indications, if any.
-
Market Expansion: As awareness increases, utilization may reach 30–40% of the target demographic.
Long-term (beyond 5 years)
- Potential Price Adjustment: Possible discounts or price reductions due to payer negotiations or biosimilar entry, but limited biosimilar competition for rare disease drugs. Prices may hover around $100,000–$125,000 annually.
How Does Competition Affect Pricing?
-
Limited Competition: No direct competitors for FSGS or pMN at present, providing pricing power.
-
Potential Competitors: Other immunosuppressive agents and off-label treatments could pose threats; however, none are specifically approved for similar indications with proven efficacy like Sparsentan.
-
Biosimilar or Replacement Technologies: Lack of biosimilar options diminishes downward price pressure.
What Are Other Factors Influencing Pricing?
-
Regulatory Milestones: FDA approval will enable commercialization, influencing initial launch pricing.
-
Reimbursement Policies: Price negotiations with payers may reduce net prices over time.
-
Clinical Outcomes: Demonstrated superiority over existing therapies can justify premium pricing.
Summary of Key Data
| Aspect |
Details |
| Indications |
FSGS, pMN |
| Estimated Patient Base |
10,000–15,000 in the U.S. |
| Initial Price Range |
$100,000–$125,000 per year |
| Long-term Price Range |
$100,000–$150,000 per year |
| Competitors |
No direct competition for specific indications, high pricing power |
| Market Penetration |
Begins at 10-20%, potentially rises to 30–40% over several years |
Key Takeaways
- The market for Sparsentan hinges on its approval for rare kidney diseases affecting small patient populations.
- Pricing is expected to be high initially, consistent with orphan drug precedents, and may undergo minor adjustments over time.
- Limited competition grants pricing power, but reimbursement negotiations and clinical outcomes will influence the ultimate price realized.
- Market penetration will depend on clinician adoption, patient access, and payer coverage.
- Long-term pricing stability relies on sustained efficacy, safety, and regulatory exclusivity.
FAQs
1. When is Sparsentan expected to gain FDA approval?
Trial completion data from Phase 3 studies is anticipated in 2023–2024, with potential approval in late 2024 or early 2025.
2. What factors could lower pricing expectations?
Introduction of biosimilars, regulatory or safety issues, or reimbursement challenges could drive prices downward.
3. How does orphan drug designation impact pricing?
It grants market exclusivity and often leads to premium pricing, typically exceeding $100,000 annually.
4. Are there existing therapies for FSGS and pMN?
Yes, but they have limitations. Standard treatments include corticosteroids and immunosuppressants, often with significant side effects.
5. What is the outlook for reimbursement for Sparsentan?
Given its orphan designation and targeted indication, coverage is likely favorable, but negotiations with payers remain essential to ensure patient access.
References
- Nephrology Dialysis Transplantation. Incidence and prevalence of FSGS. 2017.
- Kidney International. Incidence of primary membranous nephropathy. 2018.
